<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184859</url>
  </required_header>
  <id_info>
    <org_study_id>FE992026 CS36</org_study_id>
    <nct_id>NCT01184859</nct_id>
  </id_info>
  <brief_title>Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo</brief_title>
  <acronym>NOC</acronym>
  <official_title>A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-group, Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo in Water-loaded Male and Female Japanese Nocturia Patients (Single Dose), and to Study the Efficacy of 4 Different Dose Levels of Minirin Melt and Placebo After 28 Days of Dosing (Multiple Doses)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group
      comparative trial to be conducted in nocturia patients. The trial is designed to characterize
      the dose-response relationship of Minirin (desmopressin) Melt in order to establish correct
      dose recommendations in the target patient population. In particular, the trial is designed
      to link the duration of action to the clinical endpoint. Furthermore, the trial is designed
      to describe the safety of four different dose levels of desmopressin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Action Defined as the Time With Urine Osmolality Above 200 mOsm/kg - Period 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Participants were water-loaded to suppress the endogenous release of vasopressin, thus all antidiuretic activity was generated by desmopressin only. Water-loading was initiated 2 hours before dosing on Day 1. Urine volume was registered and samples for osmolality check were collected every 30 minutes as long as there was an antidiuretic action defined as a urine production &lt;0.12 mL/kg/min. The hydration should have lasted until end of action, defined as when the urine production returned to &gt;0.12 mL/kg/min, but no longer than 12 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Number of Nocturnal Voids After 28 Days of Treatment - Period 2</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average number of nocturnal voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Urine Osmolality Curve (AUCosm)</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the urine osmolality curve, from dose administration to end of action (AUCosm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Urine Production Curve (AUCurine Prod)</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the urine production curve, from dose administration to end of action (AUCurine prod)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time When Urine Production &lt;0.12 ml/kg/Min</measure>
    <time_frame>Day 1</time_frame>
    <description>Urine volume was registered and samples for osmolality check were collected every 30 minutes as long as there was an antidiuretic action defined as a urine production &lt;0.12 mL/kg/min. The hydration due to water-loading should have lasted until end of action, defined as when the urine production returned to &gt;0.12 mL/kg/min, but no longer than 12 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duration of First Period of Undisturbed Sleep After 28 Days of Treatment - Period 2</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Duration of first period of undisturbed sleep is defined as the length of time from initial sleep to first awakening.
Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average length of first period of undisturbed sleep of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Sleep Time at Approximately Day 32</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Total sleep time is defined as the time spent asleep from initial sleep to final awakening.
Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average of the total time asleep of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Daytime Voids at Approximately Day 32</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Number of daytime voids was recorded over three consecutive days per week in diaries kept by study participants. The average number of daytime voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of 24-hour Urine Voids at Approximately Day 32</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Number of voids in 24 hours was recorded over three consecutive days per week in diaries kept by study participants. The average number of 24-hour voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturnal Urine Volume at Approximately Day 32</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Nocturnal urine volume was recorded over three consecutive days per week in diaries kept by study participants. The average nocturnal urine volume of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-Hour Urine Volume at Approximately Day 32</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Twenty-four hour urine volume was recorded over three consecutive days per week in diaries kept by study participants. The average 24-hour urine volume of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-Hour Urine Production Per Body Weight at Approximately Day 32</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Twenty-four hour urine volume was recorded over three consecutive days per week in diaries kept by study participants. Urine volume per body weight was calculated. The average 24-hour urine volume per kg of body weight of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturnal Polyuria Index at Approximately Day 32</measure>
    <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
    <description>Nocturnal polyuria index is defined as a proportion of nocturnal urine volume to the 24-hour urine volume. Urine volume and time of day of those voids was recorded over three consecutive days per week in diaries kept by study participants. The average nocturnal polyuria index of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturia-Related Quality of Life Based on Evaluation Provided by Nocturia Quality of Life Questionnaire (N-QoL) at Approximately Day 32</measure>
    <time_frame>Approximately Day 4 (start of period 2) and Day 32</time_frame>
    <description>N-QoL assesses the impact of nocturia on quality of life (QoL) and treatment outcomes. N-QoL is a self-administered questionnaire with 13 items using scales of 0 = no negative impact to QoL to the upper number = signficant negative impact to QoL. The sleep/energy domain consists of 7 questions with a scale of 0 to 28. The bother/concern domain consists of 5 questions for a scale of 0 to 20. The 13th question is an overall assessment scored from 0 to 10. The Total Score includes all 13 questions with a scale of 0 (no negative impact to QoL) to 58 (significant negative impact to QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sleep Related Quality of Life Based on the Global Score of the Pittsburgh Sleep Quality Index (PSQI) at Approximately Day 32</measure>
    <time_frame>Approximately Day 4 (start of period 2) and Day 32</time_frame>
    <description>The Global Score of the Pittsburgh Sleep Quality Index (PSQI) is comprised of Questions 2-9 with a total scale of 0 (no difficulty sleeping) to 21 (severe difficulty). The change in Global Score is Global Score at the end of period 2 (day 32) - Global Score at the start of Period 2 (day 4). A negative change indicates an improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Counts of Minimum Observed Serum Sodium Levels During the Second Treatment Period (Days 4-32)</measure>
    <time_frame>Days 4- 32</time_frame>
    <description>Serum sodium levels were monitored throughout the trial as part of the clinical chemistry panel. If the value was ≤125 mEq/L, the participant was to be withdrawn from the trial and treatment stopped immediately. This outcome reports participants' lowest recorded serum sodium levels during the second treatment period.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Desmopressin 10µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin 25µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin 50µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin 100µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <description>Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration</description>
    <arm_group_label>Desmopressin 10µg</arm_group_label>
    <arm_group_label>Desmopressin 25µg</arm_group_label>
    <arm_group_label>Desmopressin 50µg</arm_group_label>
    <arm_group_label>Desmopressin 100µg</arm_group_label>
    <other_name>FE992026</other_name>
    <other_name>Minirin Melt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo melt tablet for sublingual administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Given written informed consent prior to any trial-related activity is performed

          -  Aged 55-75 years

          -  Mean number of nocturnal voids of at least two per night

          -  Reached post-menopause (applicable to females only)

        Exclusion Criteria:

          -  Evidence of bladder outlet obstruction (BOO); or a urine flow of less than 5 mL/s
             (applicable to males only)

          -  A surgical treatment for BOO or prostatic hyperplasia within the past 6 months
             (applicable to males only)

          -  Showing symptoms of any of the following diseases and having a mean number of
             nocturnal voids exceeding four per night: Benign prostatic hyperplasia, overactive
             bladder, interstitial cystitis, severe stress urinary incontinence

          -  Psychosomatic or habitual polydipsia

          -  Urinary retention; or a post void residual volume in excess of 150 mL

          -  A history or complication of urologic malignancy (e.g. bladder cancer or prostate
             cancer)

          -  Complication of genito-urinary pathology (e.g. infection, stone, or neoplasia)

          -  Complication of neurogenic detrusor activity

          -  Complication or suspicion of heart failure

          -  Uncontrolled hypertension

          -  Uncontrolled diabetes mellitus

          -  Complication of hepatobiliary disease

          -  Abnormal serum creatinine level

          -  Complication of hyponatraemia, or serum sodium level &lt;135 mEq/L

          -  Central or nephrogenic diabetes insipidus (CDI or NDI)

          -  Syndrome of inappropriate antidiuretic hormone (SIADH)

          -  Obstructive sleep apnea

          -  Alcohol dependency or drug abuse

          -  A job or lifestyle that may interfere with regular night-time sleep

          -  Previous desmopressin treatment

          -  Treatment with another investigational product within the past 3 months

          -  A need for treatment with a prohibited concomitant drug for a complication or other
             problem

          -  A mental condition, the lack of decision-making ability, dementia or a speech handicap

          -  Any other reason that the Investigator believes inappropriate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daiichi Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Geriatrics and Gerontology</name>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokuho Asahi Central Hospital</name>
      <address>
        <city>Asahi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Yoshida</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takayama Hospital</name>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houshikai Group Kano Hospital</name>
      <address>
        <city>Koga</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jyusendo General Hospital</name>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Insurance Nihonmatsu Hospital</name>
      <address>
        <city>Nihonmatsu</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takayama Clinic</name>
      <address>
        <city>Awagi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kobe Medical Center</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Mito Hospital</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Shin-midori General Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Rosai Hospital</name>
      <address>
        <city>Yatsushiro</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senbokufujii Hospital</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Medical Center East</name>
      <address>
        <city>Arakawa</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koganeibashi Sakura Clinic</name>
      <address>
        <city>Koganei</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunitachi Sakura Hospital</name>
      <address>
        <city>Kunitachi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harasanshin Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saku Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Urological Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakuin Urogenital Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Red Cross Hospital</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohara General Hospital</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Fukushima General Hospital</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jigenji Kubo Clinic</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawahara Hinyoukika</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yagi Clinic</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rakusai Newtown Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzuki Urological Clinic</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanri Urological Clinic</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <results_first_submitted>April 24, 2012</results_first_submitted>
  <results_first_submitted_qc>April 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2012</results_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nocturia</keyword>
  <keyword>bladder function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>139 patients randomized and 116 treated. Withdrawals during the screening period were due to urine production did not meet &gt;0.12 mL/kg/min within 2 hours of dosing (22 patients) and violation of inclusion/exclusion criteria (1 patient).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Desmopressin 10µg</title>
          <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="P3">
          <title>Desmopressin 25µg</title>
          <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Desmopressin 50µg</title>
          <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="P5">
          <title>Desmopressin 100µg</title>
          <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Single Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23">2 participants disqualified due to no post-baseline primary efficacy data, and/or 'other'.</participants>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="21">1 participant disqualified due to major entry criteria violation</participants>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol (PP)</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="23">1 additional participant disqualified due to 'other'.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient urine production</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Daily Dose for 28 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Desmopressin 10µg</title>
          <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Desmopressin 25µg</title>
          <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Desmopressin 50µg</title>
          <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Desmopressin 100µg</title>
          <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>FAS population is used for the Baseline Measures</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="6.4"/>
                    <measurement group_id="B2" value="67.0" spread="5.6"/>
                    <measurement group_id="B3" value="65.5" spread="6.0"/>
                    <measurement group_id="B4" value="64.9" spread="7.1"/>
                    <measurement group_id="B5" value="65.3" spread="5.6"/>
                    <measurement group_id="B6" value="65.4" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=55 and &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 and &lt;76 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Nocturnal Voids</title>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.16" spread="0.26"/>
                    <measurement group_id="B2" value="2.43" spread="0.51"/>
                    <measurement group_id="B3" value="2.45" spread="0.45"/>
                    <measurement group_id="B4" value="2.29" spread="0.44"/>
                    <measurement group_id="B5" value="2.26" spread="0.38"/>
                    <measurement group_id="B6" value="2.32" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Daytime Voids</title>
          <units>daytime voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.67" spread="1.48"/>
                    <measurement group_id="B2" value="7.97" spread="1.91"/>
                    <measurement group_id="B3" value="8.70" spread="1.53"/>
                    <measurement group_id="B4" value="8.67" spread="1.99"/>
                    <measurement group_id="B5" value="8.33" spread="1.65"/>
                    <measurement group_id="B6" value="8.26" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of 24-hour Voids</title>
          <units>voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.83" spread="1.52"/>
                    <measurement group_id="B2" value="10.41" spread="1.94"/>
                    <measurement group_id="B3" value="11.15" spread="1.79"/>
                    <measurement group_id="B4" value="10.95" spread="2.12"/>
                    <measurement group_id="B5" value="10.60" spread="1.60"/>
                    <measurement group_id="B6" value="10.58" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nocturnal Urine Volume</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="634.78" spread="210.54"/>
                    <measurement group_id="B2" value="568.55" spread="227.40"/>
                    <measurement group_id="B3" value="613.06" spread="182.47"/>
                    <measurement group_id="B4" value="635.87" spread="211.53"/>
                    <measurement group_id="B5" value="631.78" spread="175.02"/>
                    <measurement group_id="B6" value="616.64" spread="200.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-Hour Urine Volume</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1742.32" spread="344.99"/>
                    <measurement group_id="B2" value="1632.17" spread="454.75"/>
                    <measurement group_id="B3" value="1881.67" spread="399.42"/>
                    <measurement group_id="B4" value="1848.32" spread="497.96"/>
                    <measurement group_id="B5" value="1785.65" spread="404.67"/>
                    <measurement group_id="B6" value="1775.93" spread="423.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Action Defined as the Time With Urine Osmolality Above 200 mOsm/kg - Period 1</title>
        <description>Participants were water-loaded to suppress the endogenous release of vasopressin, thus all antidiuretic activity was generated by desmopressin only. Water-loading was initiated 2 hours before dosing on Day 1. Urine volume was registered and samples for osmolality check were collected every 30 minutes as long as there was an antidiuretic action defined as a urine production &lt;0.12 mL/kg/min. The hydration should have lasted until end of action, defined as when the urine production returned to &gt;0.12 mL/kg/min, but no longer than 12 hours.</description>
        <time_frame>Day 1</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Action Defined as the Time With Urine Osmolality Above 200 mOsm/kg - Period 1</title>
          <description>Participants were water-loaded to suppress the endogenous release of vasopressin, thus all antidiuretic activity was generated by desmopressin only. Water-loading was initiated 2 hours before dosing on Day 1. Urine volume was registered and samples for osmolality check were collected every 30 minutes as long as there was an antidiuretic action defined as a urine production &lt;0.12 mL/kg/min. The hydration should have lasted until end of action, defined as when the urine production returned to &gt;0.12 mL/kg/min, but no longer than 12 hours.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.09" spread="0.32"/>
                    <measurement group_id="O3" value="2.00" spread="3.56"/>
                    <measurement group_id="O4" value="3.45" spread="2.88"/>
                    <measurement group_id="O5" value="5.74" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.211</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Number of Nocturnal Voids After 28 Days of Treatment - Period 2</title>
        <description>Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average number of nocturnal voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Nocturnal Voids After 28 Days of Treatment - Period 2</title>
          <description>Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average number of nocturnal voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>nocturnal voids</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.735" lower_limit="-1.049" upper_limit="-0.421"/>
                    <measurement group_id="O2" value="-1.007" lower_limit="-1.320" upper_limit="-0.695"/>
                    <measurement group_id="O3" value="-1.282" lower_limit="-1.583" upper_limit="-0.981"/>
                    <measurement group_id="O4" value="-1.589" lower_limit="-1.903" upper_limit="-1.274"/>
                    <measurement group_id="O5" value="-1.624" lower_limit="-1.999" upper_limit="-1.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Gender is a factor, and duration of action and baseline number of nocturnal voids are covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.272</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.685</ci_lower_limit>
            <ci_upper_limit>-0.141</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Gender is a factor, and duration of action and baseline number of nocturnal voids are covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.547</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.985</ci_lower_limit>
            <ci_upper_limit>-0.108</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Gender is a factor, and duration of action and baseline number of nocturnal voids are covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.854</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.317</ci_lower_limit>
            <ci_upper_limit>-0.391</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, because this study was not a confirmatory trial. A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Gender is a factor, and duration of action and baseline number of nocturnal voids are covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.888</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.426</ci_lower_limit>
            <ci_upper_limit>-0.351</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Urine Osmolality Curve (AUCosm)</title>
        <description>Area under the urine osmolality curve, from dose administration to end of action (AUCosm).</description>
        <time_frame>Day 1</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Urine Osmolality Curve (AUCosm)</title>
          <description>Area under the urine osmolality curve, from dose administration to end of action (AUCosm).</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
          <units>h*mOsm/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="24.67" spread="97.50"/>
                    <measurement group_id="O3" value="852.00" spread="1576.10"/>
                    <measurement group_id="O4" value="1551.01" spread="1501.21"/>
                    <measurement group_id="O5" value="3112.53" spread="2131.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Urine Production Curve (AUCurine Prod)</title>
        <description>Area under the urine production curve, from dose administration to end of action (AUCurine prod)</description>
        <time_frame>Day 1</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Urine Production Curve (AUCurine Prod)</title>
          <description>Area under the urine production curve, from dose administration to end of action (AUCurine prod)</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
          <units>h*mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.34" spread="153.78"/>
                    <measurement group_id="O2" value="214.24" spread="266.86"/>
                    <measurement group_id="O3" value="297.17" spread="322.51"/>
                    <measurement group_id="O4" value="522.99" spread="283.90"/>
                    <measurement group_id="O5" value="537.08" spread="330.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time When Urine Production &lt;0.12 ml/kg/Min</title>
        <description>Urine volume was registered and samples for osmolality check were collected every 30 minutes as long as there was an antidiuretic action defined as a urine production &lt;0.12 mL/kg/min. The hydration due to water-loading should have lasted until end of action, defined as when the urine production returned to &gt;0.12 mL/kg/min, but no longer than 12 hours.</description>
        <time_frame>Day 1</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time When Urine Production &lt;0.12 ml/kg/Min</title>
          <description>Urine volume was registered and samples for osmolality check were collected every 30 minutes as long as there was an antidiuretic action defined as a urine production &lt;0.12 mL/kg/min. The hydration due to water-loading should have lasted until end of action, defined as when the urine production returned to &gt;0.12 mL/kg/min, but no longer than 12 hours.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="1.15"/>
                    <measurement group_id="O2" value="1.67" spread="2.16"/>
                    <measurement group_id="O3" value="3.50" spread="4.17"/>
                    <measurement group_id="O4" value="6.05" spread="3.56"/>
                    <measurement group_id="O5" value="8.20" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duration of First Period of Undisturbed Sleep After 28 Days of Treatment - Period 2</title>
        <description>Duration of first period of undisturbed sleep is defined as the length of time from initial sleep to first awakening.
Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average length of first period of undisturbed sleep of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duration of First Period of Undisturbed Sleep After 28 Days of Treatment - Period 2</title>
          <description>Duration of first period of undisturbed sleep is defined as the length of time from initial sleep to first awakening.
Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average length of first period of undisturbed sleep of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.39" spread="93.32"/>
                    <measurement group_id="O2" value="101.85" spread="120.26"/>
                    <measurement group_id="O3" value="113.45" spread="120.22"/>
                    <measurement group_id="O4" value="190.77" spread="124.32"/>
                    <measurement group_id="O5" value="194.25" spread="99.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Sleep Time at Approximately Day 32</title>
        <description>Total sleep time is defined as the time spent asleep from initial sleep to final awakening.
Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average of the total time asleep of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Sleep Time at Approximately Day 32</title>
          <description>Total sleep time is defined as the time spent asleep from initial sleep to final awakening.
Records of nocturia and sleep over three consecutive days per week were kept in voiding-sleep diaries by study participants. The average of the total time asleep of the 3 days recorded in the last week of the study (between study days 25-32) was compared to average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="49.94"/>
                    <measurement group_id="O2" value="-11.86" spread="48.57"/>
                    <measurement group_id="O3" value="-33.04" spread="116.09"/>
                    <measurement group_id="O4" value="6.81" spread="69.04"/>
                    <measurement group_id="O5" value="14.07" spread="54.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Daytime Voids at Approximately Day 32</title>
        <description>Number of daytime voids was recorded over three consecutive days per week in diaries kept by study participants. The average number of daytime voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Daytime Voids at Approximately Day 32</title>
          <description>Number of daytime voids was recorded over three consecutive days per week in diaries kept by study participants. The average number of daytime voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="1.33"/>
                    <measurement group_id="O2" value="0.68" spread="1.53"/>
                    <measurement group_id="O3" value="0.15" spread="1.66"/>
                    <measurement group_id="O4" value="0.23" spread="1.51"/>
                    <measurement group_id="O5" value="0.63" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of 24-hour Urine Voids at Approximately Day 32</title>
        <description>Number of voids in 24 hours was recorded over three consecutive days per week in diaries kept by study participants. The average number of 24-hour voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of 24-hour Urine Voids at Approximately Day 32</title>
          <description>Number of voids in 24 hours was recorded over three consecutive days per week in diaries kept by study participants. The average number of 24-hour voids of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.71"/>
                    <measurement group_id="O2" value="-0.47" spread="1.93"/>
                    <measurement group_id="O3" value="-1.19" spread="1.85"/>
                    <measurement group_id="O4" value="-1.33" spread="1.81"/>
                    <measurement group_id="O5" value="-0.96" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturnal Urine Volume at Approximately Day 32</title>
        <description>Nocturnal urine volume was recorded over three consecutive days per week in diaries kept by study participants. The average nocturnal urine volume of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Urine Volume at Approximately Day 32</title>
          <description>Nocturnal urine volume was recorded over three consecutive days per week in diaries kept by study participants. The average nocturnal urine volume of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-114.70" spread="224.53"/>
                    <measurement group_id="O2" value="-140.68" spread="168.62"/>
                    <measurement group_id="O3" value="-209.87" spread="262.89"/>
                    <measurement group_id="O4" value="-295.02" spread="196.71"/>
                    <measurement group_id="O5" value="-333.22" spread="154.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-Hour Urine Volume at Approximately Day 32</title>
        <description>Twenty-four hour urine volume was recorded over three consecutive days per week in diaries kept by study participants. The average 24-hour urine volume of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-Hour Urine Volume at Approximately Day 32</title>
          <description>Twenty-four hour urine volume was recorded over three consecutive days per week in diaries kept by study participants. The average 24-hour urine volume of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-104.47" spread="386.27"/>
                    <measurement group_id="O2" value="-19.47" spread="371.72"/>
                    <measurement group_id="O3" value="-201.83" spread="487.49"/>
                    <measurement group_id="O4" value="-270.53" spread="344.29"/>
                    <measurement group_id="O5" value="-187.25" spread="369.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-Hour Urine Production Per Body Weight at Approximately Day 32</title>
        <description>Twenty-four hour urine volume was recorded over three consecutive days per week in diaries kept by study participants. Urine volume per body weight was calculated. The average 24-hour urine volume per kg of body weight of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-Hour Urine Production Per Body Weight at Approximately Day 32</title>
          <description>Twenty-four hour urine volume was recorded over three consecutive days per week in diaries kept by study participants. Urine volume per body weight was calculated. The average 24-hour urine volume per kg of body weight of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>ml/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.017" spread="6.205"/>
                    <measurement group_id="O2" value="-0.096" spread="6.814"/>
                    <measurement group_id="O3" value="-3.523" spread="7.621"/>
                    <measurement group_id="O4" value="-4.573" spread="6.183"/>
                    <measurement group_id="O5" value="-3.058" spread="6.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturnal Polyuria Index at Approximately Day 32</title>
        <description>Nocturnal polyuria index is defined as a proportion of nocturnal urine volume to the 24-hour urine volume. Urine volume and time of day of those voids was recorded over three consecutive days per week in diaries kept by study participants. The average nocturnal polyuria index of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
        <time_frame>3 days between study days -6 to 0 (Baseline), and days 25 to 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Polyuria Index at Approximately Day 32</title>
          <description>Nocturnal polyuria index is defined as a proportion of nocturnal urine volume to the 24-hour urine volume. Urine volume and time of day of those voids was recorded over three consecutive days per week in diaries kept by study participants. The average nocturnal polyuria index of the 3 days recorded in the last week of the study (between study days 25-32) was compared to the average baseline readings.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>nocturnal urine volume / 24-hour urine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.72" spread="6.75"/>
                    <measurement group_id="O2" value="-7.82" spread="6.65"/>
                    <measurement group_id="O3" value="-8.61" spread="9.28"/>
                    <measurement group_id="O4" value="-13.56" spread="9.72"/>
                    <measurement group_id="O5" value="-16.00" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturia-Related Quality of Life Based on Evaluation Provided by Nocturia Quality of Life Questionnaire (N-QoL) at Approximately Day 32</title>
        <description>N-QoL assesses the impact of nocturia on quality of life (QoL) and treatment outcomes. N-QoL is a self-administered questionnaire with 13 items using scales of 0 = no negative impact to QoL to the upper number = signficant negative impact to QoL. The sleep/energy domain consists of 7 questions with a scale of 0 to 28. The bother/concern domain consists of 5 questions for a scale of 0 to 20. The 13th question is an overall assessment scored from 0 to 10. The Total Score includes all 13 questions with a scale of 0 (no negative impact to QoL) to 58 (significant negative impact to QoL).</description>
        <time_frame>Approximately Day 4 (start of period 2) and Day 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturia-Related Quality of Life Based on Evaluation Provided by Nocturia Quality of Life Questionnaire (N-QoL) at Approximately Day 32</title>
          <description>N-QoL assesses the impact of nocturia on quality of life (QoL) and treatment outcomes. N-QoL is a self-administered questionnaire with 13 items using scales of 0 = no negative impact to QoL to the upper number = signficant negative impact to QoL. The sleep/energy domain consists of 7 questions with a scale of 0 to 28. The bother/concern domain consists of 5 questions for a scale of 0 to 20. The 13th question is an overall assessment scored from 0 to 10. The Total Score includes all 13 questions with a scale of 0 (no negative impact to QoL) to 58 (significant negative impact to QoL).</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep/Energy subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.77" spread="11.66"/>
                    <measurement group_id="O2" value="10.69" spread="15.33"/>
                    <measurement group_id="O3" value="13.26" spread="15.46"/>
                    <measurement group_id="O4" value="12.30" spread="10.82"/>
                    <measurement group_id="O5" value="8.52" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother/Concern subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="19.02"/>
                    <measurement group_id="O2" value="8.99" spread="16.91"/>
                    <measurement group_id="O3" value="16.33" spread="18.35"/>
                    <measurement group_id="O4" value="10.67" spread="19.37"/>
                    <measurement group_id="O5" value="10.15" spread="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.04" spread="14.05"/>
                    <measurement group_id="O2" value="9.98" spread="14.65"/>
                    <measurement group_id="O3" value="14.78" spread="16.28"/>
                    <measurement group_id="O4" value="11.44" spread="13.00"/>
                    <measurement group_id="O5" value="9.39" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sleep Related Quality of Life Based on the Global Score of the Pittsburgh Sleep Quality Index (PSQI) at Approximately Day 32</title>
        <description>The Global Score of the Pittsburgh Sleep Quality Index (PSQI) is comprised of Questions 2-9 with a total scale of 0 (no difficulty sleeping) to 21 (severe difficulty). The change in Global Score is Global Score at the end of period 2 (day 32) - Global Score at the start of Period 2 (day 4). A negative change indicates an improvement in quality of life.</description>
        <time_frame>Approximately Day 4 (start of period 2) and Day 32</time_frame>
        <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sleep Related Quality of Life Based on the Global Score of the Pittsburgh Sleep Quality Index (PSQI) at Approximately Day 32</title>
          <description>The Global Score of the Pittsburgh Sleep Quality Index (PSQI) is comprised of Questions 2-9 with a total scale of 0 (no difficulty sleeping) to 21 (severe difficulty). The change in Global Score is Global Score at the end of period 2 (day 32) - Global Score at the start of Period 2 (day 4). A negative change indicates an improvement in quality of life.</description>
          <population>Per protocol population, consisting of treated participants without major protocol violations and with &gt;=80% treatment compliance. Missing values post baseline were imputed using last observation carried forward (LOCF) where at least one post baseline measurement was available at a visit before the missing observation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.0"/>
                    <measurement group_id="O2" value="-0.6" spread="2.3"/>
                    <measurement group_id="O3" value="-1.5" spread="2.2"/>
                    <measurement group_id="O4" value="-1.4" spread="2.5"/>
                    <measurement group_id="O5" value="-1.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Counts of Minimum Observed Serum Sodium Levels During the Second Treatment Period (Days 4-32)</title>
        <description>Serum sodium levels were monitored throughout the trial as part of the clinical chemistry panel. If the value was ≤125 mEq/L, the participant was to be withdrawn from the trial and treatment stopped immediately. This outcome reports participants' lowest recorded serum sodium levels during the second treatment period.</description>
        <time_frame>Days 4- 32</time_frame>
        <population>Safety population which included all randomised and exposed participants. Participants were analysed according to the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin 10µg</title>
            <description>Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin 25µg</title>
            <description>Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin 50µg</title>
            <description>Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin 100µg</title>
            <description>Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Counts of Minimum Observed Serum Sodium Levels During the Second Treatment Period (Days 4-32)</title>
          <description>Serum sodium levels were monitored throughout the trial as part of the clinical chemistry panel. If the value was ≤125 mEq/L, the participant was to be withdrawn from the trial and treatment stopped immediately. This outcome reports participants' lowest recorded serum sodium levels during the second treatment period.</description>
          <population>Safety population which included all randomised and exposed participants. Participants were analysed according to the actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 135 mEq/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=130 mEq/L to &lt;135 mEq/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;130 mEq/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Period 1: Day 1 to Day 3 (includes Wash-out period) Period 2: Day 4 (first day of period 2 drug administration) to Day 32 (last day of drug administration or date of withdrawal)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo-Period 1</title>
          <description>Study period 1: single dose of placebo.</description>
        </group>
        <group group_id="E2">
          <title>Desmopressin 10µg - Period 1</title>
          <description>Study period 1: single dose of desmopressin 10µg.</description>
        </group>
        <group group_id="E3">
          <title>Desmopressin 25µg - Period 1</title>
          <description>Study period 1: single dose of desmopressin 25µg.</description>
        </group>
        <group group_id="E4">
          <title>Desmopressin 50µg - Period 1</title>
          <description>Study period 1: single dose of desmopressin 50µg.</description>
        </group>
        <group group_id="E5">
          <title>Desmopressin 100µg - Period 1</title>
          <description>Study period 1: single dose of desmopressin 100µg.</description>
        </group>
        <group group_id="E6">
          <title>Placebo - Period 2</title>
          <description>Study period 2: daily doses of placebo taken before bedtime for 28 days.</description>
        </group>
        <group group_id="E7">
          <title>Desmopressin 10µg - Period 2</title>
          <description>Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="E8">
          <title>Desmopressin 25µg - Period 2</title>
          <description>Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="E9">
          <title>Desmopressin 50µg - Period 2</title>
          <description>Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.</description>
        </group>
        <group group_id="E10">
          <title>Desmopressin 100µg - Period 2</title>
          <description>Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

